How A Team-Based Approach Works For Treatment of Brain Tumors

Video

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, explains what a team approach should look like when treating brain tumors and other rare cancers.

At the American Society of Clinical Oncology (ASCO) 2018 annual meeting in Chicago, Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, explained what a team approach should look like when treating brain tumors and other rare cancers.

Dr Ahluwalia: I can give you an example of brain tumors since I am a medical/neuro-oncologist working in Cleveland Clinic. We have 6 neurosurgeons who are dedicated to brain tumors only; we have 4 radiation oncologists who treat patients with brain tumors; and we have 4 medical/neuro-oncologists who treat patients with brain tumors.

Any patient who comes in [to the Cleveland Clinic] will see a neurosurgeon who is specialized in treating patients with brain tumors. Once they [the patients] are done with surgery, treatment often involves use of radiation along with chemotherapy, targeted therapy, or immunotherapy. They will see a radiation oncologist and a medical or neuro-oncologist.

It’s a team-based approach where we discuss the care of our patients in a tumor board, which is multidisciplinary, again. We have a neuroradiologist on the board and a neuropathologist. We discuss the genetic changes that may have occurred in patients’ tumors, which may make them an ideal candidate for a particular drug. Or, we try to discuss what are the best clinical trials for that particular patient, which may be better than the standard-of-care options available to that patient. All in all, it’s a team-based approach we take in taking care of our patients.

For more exclusive 2018 ASCO coverage, be sure to sign up to receive Rare Disease Report’s email updates.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.